Peer review reports
From: Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study
Original Submission |
20 Feb 2022 |
Submitted |
Original manuscript
|
Resubmission - Version 2 |
|
Submitted |
Manuscript version 2
|
Resubmission - Version 3 |
|
Submitted |
Manuscript version 3
|
3 Apr 2022 |
Reviewed |
Reviewer Report
|
22 Apr 2022 |
Reviewed |
Reviewer Report
|
12 May 2022 |
Author responded |
Author comments - Lin Yang
|
Resubmission - Version 4 |
12 May 2022 |
Submitted |
Manuscript version 4
|
22 May 2022 |
Author responded |
Author comments - Lin Yang
|
Resubmission - Version 5 |
22 May 2022 |
Submitted |
Manuscript version 5
|
15 Jun 2022 |
Reviewed |
Reviewer Report
|
24 Jun 2022 |
Author responded |
Author comments - Lin Yang
|
Resubmission - Version 6 |
24 Jun 2022 |
Submitted |
Manuscript version 6
|
Publishing |
4 Jul 2022 |
Editorially accepted |
|
21 Jul 2022 |
Article published |
10.1186/s12885-022-09889-3
|
Learn about peer review